Letrozole and Cutaneous vasculitis - a phase IV clinical study of FDA data

Summary:

Cutaneous vasculitis is reported as a side effect among people who take Letrozole (letrozole), especially for people who are female, 60+ old, also take Anastrozole, and have Toxic nodular goitre.

The phase IV clinical study analyzes which people have Cutaneous vasculitis when taking Letrozole. It is created by eHealthMe based on reports of 53,470 people who have side effects when taking Letrozole from the FDA, and is updated regularly.

What is Letrozole?

Letrozole has active ingredients of letrozole. It is often used in breast cancer. eHealthMe is studying from 54,125 Letrozole users. Check the latest studies of Letrozole.

What is Cutaneous vasculitis?

Cutaneous vasculitis (an inflammatory process affecting the vessel wall that leads to its damage) is found to be associated with 245 drugs and 344 conditions by eHealthMe. Check the latest studies of Cutaneous vasculitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

53,470 people reported to have side effects when taking Letrozole.
Among them, 25 people (0.05%) have Cutaneous vasculitis.

Could Letrozole cause Cutaneous vasculitis?

Among these 25 people:

What is the gender of people who have Cutaneous vasculitis when taking Letrozole? *

female: 100 %
male: 0.0 %

What is the age of people who have Cutaneous vasculitis when taking Letrozole? *

What are other drugs people take besides Letrozole? *

What are other side effects people have besides Cutaneous vasculitis? *

Joint Pain: 5 people, 20.00%
Rashes (redness): 5 people, 20.00%
Cutaneous Lupus Erythematosus (own immune system attacks various cells causing a wide variety of signs and symptoms): 5 people, 20.00%
Drug Eruption (adverse drug reaction of the skin): 5 people, 20.00%
Toxic Nodular Goitre (a thyroid gland that contains autonomously functioning thyroid nodules, with resulting excess thyroid hormone secretion): 4 people, 16.00%
Connective Tissue Disorder (any disease that has the connective tissues of the body): 4 people, 16.00%
Weight Decreased: 3 people, 12.00%
Skin Ulcer: 3 people, 12.00%
Purpura (purplish discoloration of the skin): 3 people, 12.00%
Wound Secretion: 2 people, 8.00%

What are the existing conditions these people have? *

Toxic Nodular Goitre (a thyroid gland that contains autonomously functioning thyroid nodules, with resulting excess thyroid hormone secretion): 5 people, 20.00%
Joint Pain: 2 people, 8.00%
High Blood Pressure: 2 people, 8.00%
Breast Cancer Stage Iv: 2 people, 8.00%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 8.00%
Asthma: 2 people, 8.00%
Oestrogen Receptor Assay Positive: 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Letrozole and have Cutaneous vasculitis?

- Check whether Cutaneous vasculitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Letrozole:

Letrozole (54,125 reports)

Browse all side effects of Letrozole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cutaneous vasculitis:

Cutaneous vasculitis (245 drugs)

Browse all the conditions that are associated with Cutaneous vasculitis:

Cutaneous vasculitis (344 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on letrozole (the active ingredients of Letrozole) and Letrozole (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.